Bottom-Up EquitiesDaily Briefs

Equity Bottom-Up: Icure Pharm Inc and more

In today’s briefing:

  • Icure Pharm (175250 KS): High Hope for Transdermal Patch-Type Dementia Treatment Option

Icure Pharm (175250 KS): High Hope for Transdermal Patch-Type Dementia Treatment Option

By Tina Banerjee

  • Icure Pharm Inc (175250 KS) obtained marketing approval for world’s first donepezil patch, a treatment of Alzheimer’s-type dementia in Korea. Donepezil accounts for 80% of the local Alzheimer’s treatment market.
  • For the domestic market, donepezil is expected to generate revenue of KRW 3.4 billion, equivalent to nearly 10% of existing annual revenue, with significantly higher profitability.
  • The company is currently negotiating for sales right contract in the U.S. and aims to launch the product by 2024 in the U.S.  

Related tickers:

Before it’s here, it’s on Smartkarma